argenx (ARGX) Stock Forecast & Price Target

$365.81
-10.79 (-2.87%)
(As of 05/17/2024 ET)

argenx Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 21 Analyst Ratings

Analysts' Consensus Price Target

$524.68
43.43% Upside
High Forecast$641.00
Average Forecast$524.68
Low Forecast$408.00
TypeCurrent Forecast
5/20/23 to 5/19/24
1 Month Ago
4/20/23 to 4/19/24
3 Months Ago
2/19/23 to 2/19/24
1 Year Ago
5/20/22 to 5/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
15 Buy rating(s)
17 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$524.68$528.16$525.90$454.79
Predicted Upside43.43% Upside26.16% Upside28.53% Upside21.78% Upside
Get argenx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

ARGX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenx Stock vs. The Competition

TypeargenxMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.69
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside43.43% Upside848.97% Upside7.86% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$560.00 ➝ $500.00+34.23%
5/10/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$451.00 ➝ $448.00+19.24%
5/10/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$471.00 ➝ $468.00+25.62%
4/18/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$521.00+44.03%
3/26/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$402.00 ➝ $408.00+2.40%
3/5/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$370.00 ➝ $440.00+12.73%
3/1/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$505.00 ➝ $490.00+28.94%
2/20/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$472.00 ➝ $478.00+20.69%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoveragePeer Perform
1/26/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$518.00 ➝ $522.00+36.32%
12/21/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$594.00 ➝ $436.00+32.77%
12/21/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetStrong-Buy ➝ Strong-Buy$580.00 ➝ $520.00+53.43%
12/20/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Minter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
12/20/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
12/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$557.00 ➝ $560.00+22.28%
12/12/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$612.00 ➝ $641.00+41.35%
11/30/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$607.00 ➝ $586.00+33.20%
11/29/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$610.00 ➝ $591.00+32.71%
10/2/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$605.00 ➝ $628.00+29.56%
7/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$545.00 ➝ $590.00+17.72%
7/24/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$480.00 ➝ $570.00+3.93%
7/18/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$446.00 ➝ $572.00+18.08%
6/15/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:17 AM ET.

ARGX Price Target - Frequently Asked Questions

What is argenx's consensus rating and price target?

According to the issued ratings of 21 analysts in the last year, the consensus rating for argenx stock is Moderate Buy based on the current 1 sell rating, 5 hold ratings, 14 buy ratings and 1 strong buy rating for ARGX. The average twelve-month price prediction for argenx is $524.68 with a high price target of $641.00 and a low price target of $408.00. Learn more on ARGX's analyst rating history.

Do Wall Street analysts like argenx more than its competitors?

Analysts like argenx more than other Medical companies. The consensus rating score for argenx is 2.71 while the average consensus rating score for medical companies is 2.69. Learn more on how ARGX compares to other companies.

Does argenx's stock price have much upside?

According to analysts, argenx's stock has a predicted upside of 27.14% based on their 12-month stock forecasts.

What analysts cover argenx?

Stock Ratings Reports and Tools

This page (NASDAQ:ARGX) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners